AcelRx Pharmaceuticals Inc R5X-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 9:32 AM CEST
0.1607quote price arrow up+0.0284 (+21.47%)
52 week range
0.13 - 1.32
Loading...
  • Open0.1607
  • Day High0.1607
  • Day Low0.1607
  • Prev Close0.36
  • 52 Week High1.32
  • 52 Week High Date06/09/21
  • 52 Week Low0.13
  • 52 Week Low Date05/13/22

Key Stats

  • Market Cap28.72M
  • Shares Out136.82M
  • 10 Day Average Volume2,005.14
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-62.51

KEY STATS

  • Open0.1607
  • Day High0.1607
  • Day Low0.1607
  • Prev Close0.36
  • 52 Week High1.32
  • 52 Week High Date06/09/21
  • 52 Week Low0.13
  • 52 Week Low Date05/13/22
  • Market Cap28.72M
  • Shares Out136.82M
  • 10 Day Average Volume2,005.14
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-62.51

RATIOS/PROFITABILITY

  • EPS (TTM)-0.26
  • P/E (TTM)-0.62
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On AcelRx Pharmaceuticals Inc

There is no recent news for this security.

Profile

MORE
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Its sufentanil sublingual products include DSUVIA, DZUVEO and Zalviso, which are focused on the...
Adrian Adams
Independent Chairman of the Board
Vincent Angotti
Chief Executive Officer, Director
Raffi Asadorian
Chief Financial Officer
Address
25821 INDUSTRIAL BOULEVARD, SUITE 400
Hayward, CA
94545
United States